Senators plan to back US state Rx discounts

10 July 2001

Senators from the US states of Maine and Vermont plan to offerlegislation which would provide US states with the authority to offer the same prescription drug rebates as provided under Medicaid.

The Department of Health and Human Services does not have the authority to approve programs such as the Vermont Pharmacy Discount Program or the Healthy Maine Prescriptions program, a US Court of Appeals ruled last month (Marketletter June 18). The Pharmaceutical Research and Manufacturers of America, which launched the court challenge, said it believed such plans would put Medicaid in jeopardy.

However, Senator Olympia Snow who, with Susan Collins and James Jeffords, is developing the proposal, said "the innovative Health Maine Prescriptions program is continuing to lead the way in providing affordable prescription drugs for qualifying Maine residents," notes Reuters. The Senators plan to attach their proposal as an amendment to the Medicare prescription drug bill due before the Senate Finance Committee later this month.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight